Vivos Inc. is a radiation oncology medical device company engaged in the development of its yttrium-90 (“Y-90”) based brachytherapy device, RadioGel™, for the treatment of non-resectable tumors. A prominent team of radiochemists, scientists and engineers, collaborating with strategic partners, including national laboratories, universities and private corporations, lead the Company’s development efforts. The Company’s overall vision is to globally empower physicians, medical researchers and patients by providing them with new isotope technologies that offer safe and effective treatments for cancer.
Company profile
Ticker
RDGL
Exchange
Website
CEO
Michael K. Korenko
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
ADVANCED MEDICAL ISOTOPE Corp
SEC CIK
Corporate docs
IRS number
800138937
RDGL stock data
Latest filings (excl ownership)
10-Q
2024 Q2
Quarterly report
13 Aug 24
QUALIF
Notice of qualification
17 Jul 24
1-A/A
Offering $10.35 mm in Equity
15 Jul 24
8-K
Vivos Inc. Submits the Application to the FDA for Authority to Initiate Human Clinical Trials
1 Jul 24
1-A
Offering $10.35 mm in Equity
28 Jun 24
10-Q
2024 Q1
Quarterly report
9 May 24
8-K
Entry into a Material Definitive Agreement
22 Mar 24
10-K
2023 FY
Annual report
18 Mar 24
8-K
Unregistered Sales of Equity Securities
27 Dec 23
253G2
Offering circular supplement
21 Dec 23
Latest ownership filings
Financial summary
| Quarter (USD) | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 1.72 mm | 1.72 mm | 1.72 mm | 1.72 mm | 1.72 mm | 1.72 mm |
| Cash burn (monthly) | (no burn) | 2.03 k | 174.10 k | 238.61 k | 118.47 k | 115.99 k |
| Cash used (since last report) | n/a | 9.02 k | 774.11 k | 1.06 mm | 526.76 k | 515.74 k |
| Cash remaining | n/a | 1.72 mm | 950.30 k | 663.50 k | 1.20 mm | 1.21 mm |
| Runway (months of cash) | n/a | 845.4 | 5.5 | 2.8 | 10.1 | 10.4 |
Institutional ownership, Q2 2022
0.0% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 1 |
| Opened positions | 1 |
| Closed positions | 0 |
| Increased positions | 0 |
| Reduced positions | 0 |
| 13F shares | Current |
|---|---|
| Total value | 9.00 k |
| Total shares | 126.00 k |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Captrust Financial Advisors | 126.00 k | $9.00 k |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 28 Oct 24 | Korenko Michael K | Common Stock | Buy | Acquire P | No | No | 0.1416 | 50,000 | 7.08 k | 10,435,090 |
| 30 Sep 24 | Korenko Michael K | Common Stock | Buy | Acquire P | No | No | 0.1591 | 50,000 | 7.96 k | 10,385,090 |
| 13 Aug 24 | Korenko Michael K | Common Stock | Buy | Acquire P | No | No | 0.1119 | 50,000 | 5.60 k | 10,335,090 |
| 7 Aug 24 | Korenko Michael K | Common Stock | Buy | Acquire P | No | No | 0.1176 | 50,000 | 5.88 k | 10,285,090 |
| 1 Aug 24 | Korenko Michael K | Common Stock | Buy | Acquire P | No | No | 0.0872 | 50,000 | 4.36 k | 10,235,090 |